Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the combination of finasteride and doxazosina was more effective in reducing the long-term progression of benign prostatic hyperplasia compared to monotherapy.

This study found that a noncrosslinked hyaluronic acid filler restored cell viability against UVB-induced cytotoxicity and increased VEGF secretion in human dermal papilla cells, suggesting potential for mesotherapy use after further research.

This study reviewed the evidence on minoxidil's effectiveness for androgenetic alopecia, finding that 5% topical minoxidil is the most effective monotherapy for men, while 2% is similarly effective for women. Genetic markers can predict response, and new formulations like foam and gel improve tolerability.

In this case study, a 38-year-old woman with female androgenetic alopecia experienced increased hair density and improved hair structure following ten microneedle mesotherapy sessions combined with saw palmetto supplementation, without adverse effects.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

This study found that combining liraglutide with metformin led to greater weight loss and waist circumference reduction than either treatment alone in obese women with PCOS resistant to metformin monotherapy.

This study reported that estrogen-progestin oral contraceptives, antiandrogens, and insulin sensitizers are more effective than placebo in treating hirsutism in women, with combination therapies generally proving superior to monotherapy.

This case report observed that a child developed thrombocytopenia, characterized by a low platelet count and prolonged bleeding time, while on sodium valproate monotherapy for seizures.

This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.

This study found that breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapy experienced more pronounced vertex hair loss and were less responsive to minoxidil treatment compared to those on endocrine monotherapy.

This study reports that health-related quality of life was generally maintained, and sometimes improved, in patients with HR+/HER2- advanced or metastatic breast cancer treated with palbociclib, compared to monotherapy, across various study types.

This study evaluated oral dutasteride for male androgenetic alopecia in a real-world setting, reporting that it effectively improved hair conditions in 90% of patients using monotherapy, with a good safety profile, particularly at low doses.

This case report describes a woman with frontal fibrosing alopecia who did not improve with hydroxychloroquine and topical minoxidil but achieved clinical stabilization with methotrexate monotherapy.

In this study, topical finasteride showed mild-to-moderate improvement in androgenetic alopecia among a cohort in Saudi Arabia, with combination therapy outperforming monotherapy. Adverse events were rare. The study highlights the need for prospective trials to clarify finasteride's standalone effects.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This study found that androgenetic alopecia patients treated with a combination of PRP and systemic therapy experienced greater but non-significant improvements in hair density and width compared to PRP monotherapy, without additional adverse effects, suggesting potential benefits for further exploration of combination regimens.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

This study highlights the diverse prescribing and monitoring practices for low-dose oral minoxidil among dermatologists in the UK and Ireland, used widely for various hair loss conditions both as monotherapy and adjunctive therapy.

This study reviewed evidence on eribulin's efficacy and safety for treating metastatic triple-negative breast cancer, highlighting variable survival outcomes and manageable safety profiles for both monotherapy and combination therapies.

This case report described a patient with erosive pustular dermatosis of the scalp who was resistant to multiple treatments, suggesting that combination therapy may be more effective than monotherapy for managing refractory cases of this condition.

This prospective observational study investigated 200 patients with non-scarring alopecia, concluding that accurate classification combined with individualized treatment, including combination therapies, significantly improved outcomes over monotherapy with topical minoxidil.

This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.

In this study, a review of existing trials reported that combining minoxidil with platelet-rich plasma therapy significantly improved outcomes for androgenetic alopecia more than minoxidil alone, and offered generally superior results compared to platelet-rich plasma monotherapy, while maintaining a safe profile similar to individual treatments.

This review examines the potential roles of azathioprine and methotrexate in treating alopecia areata, concluding that both can be effective as monotherapy or in combination therapy.

In this systematic review of 728 patients, the researchers noted that combination therapies involving systemic antibiotics, topical, local, or other systemic agents may yield better outcomes and longer duration of effects for managing Folliculitis decalvans and Tufted Hair Folliculitis compared to systemic antibiotic monotherapy.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

This study found that a combination of minoxidil, microneedling, and PRP was significantly more effective than minoxidil alone in managing androgenetic alopecia over six months.

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

This study found that combining microfocused ultrasound with autologous blood cell factors significantly improved skin rejuvenation compared to using microfocused ultrasound alone.

The study did not find evidence to support using botulinum toxin as a treatment for androgenetic alopecia.